Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms, Second Primary 1 Neoplasms 1

Interventions

Cyclophosphamide 13 Bevacizumab 9 Interleukin-2 8 aldesleukin 7 Paclitaxel 7 fludarabine phosphate 6 fludarabine 6 Radiotherapy 6 Bortezomib 6 Thalidomide 5 Gemcitabine 5 Filgrastim 5 veliparib 4 sargramostim 4 Vincristine 4 Trastuzumab 4 Prednisone 4 Leucovorin 4 Doxorubicin 4 Biopsy 4 vandetanib 3 tariquidar 3 romidepsin 3 pazopanib 3 montanide ISA 51 3 Topotecan 3 Specimen Handling 3 Sorafenib 3 Sirolimus 3 Oxaliplatin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × Neoplasms × Clonidine × Clear all

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡